Weekly Report (August 9-15, 2024) Third Tranche of

New Post Public Reply Private Reply Replies (0) Message Board
News
181
Weekly Report (August 9-15, 2024) Third Tranche of Stellantis 2024 Share Buyback Program

AMSTERDAM, August 16, 2024 - Stellantis N.V. (“Stellantis” or the “Company”) announced today that pursuant to its Third Tranche of the 2024 Share Buyback Program announced on August 1, 2024, covering up to €1 billion to be executed in the open market during the period between August 1, 2024 and November 29, 2024, it has repurchased the following common shares in the period between August 9 up to and including August 15, 2024:

Date Number of Shares Repurchased Average Market Purchase Price in € per share Repurchased Volume in € (excluding fees) Venues
09/08/2024 300 000 €14.1405 €4 242 153 CEUX
09/08/2024 1 030 000 €14.1530 €14 577 609 MILE
12/08/2024 200 000 €14.0274 €2 805 486 CEUX
12/08/2024 1 225 000 €14.0534 €17 215 438 MILE
13/08/2024 300 000 €13.8250 €4 147 509 CEUX
13/08/2024 1 211 571 €13.8258 €16 750 920 MILE
14/08/2024 502 000 €14.1253 €7 090 906 MILE
15/08/2024 86 082 €14.3139 €1 232 172 CEUX
15/08/2024 363 077 €14.3150 €5 197 451 XPAR
15/08/2024 13 549 €14.3617 €194 587 TQEX
Total 5 231 279 €14.0414 €73 454 230  

Since August 1, 2024 up to and including August 15, 2024, the Company has purchased a total of 12,319,188 common shares for a total consideration of € 176,077,768.

As of August 15, 2024, the Company held in treasury No. 93.819.362 common shares equal to 2.41% of the total issued share capital including the common shares and the special voting shares.

A comprehensive overview of the transactions carried out under the buyback program, as well as the details of the above transactions, are available on Stellantis’ corporate website under the Share Buyback Program Section www.stellantis.com/en/investors/stock-and-shareholder-info/share-buyback-program .

###

About Stellantis

Stellantis N.V. (NYSE: STLA / Euronext Milan: STLAM / Euronext Paris: STLAP) is one of the world’s leading automakers aiming to provide clean, safe and affordable freedom of mobility to all. It’s best known for its unique portfolio of iconic and innovative brands including Abarth, Alfa Romeo, Chrysler, Citroën, Dodge, DS Automobiles, Fiat, Jeep®, Lancia, Maserati, Opel, Peugeot, Ram, Vauxhall, Free2move and Leasys. Stellantis is executing its Dare Forward 2030, a bold strategic plan that paves the way to achieve the ambitious target of becoming a carbon net zero mobility tech company by 2038, with single-digit percentage compensation of the remaining emissions, while creating added value for all stakeholders. For more information, visit www.stellantis.com

@Stellantis Stellantis Stellantis Stellantis
  For more information, contact: communications@stellantis.com www.stellantis.com  

FORWARD-LOOKING STATEMENTS

This communication contains forward-looking statements. In particular, statements regarding future events and anticipated results of operations, business strategies, the anticipated benefits of the proposed transaction, future financial and operating results, the anticipated closing date for the proposed transaction and other anticipated aspects of our operations or operating results are forward-looking statements. These statements may include terms such as “may”, “will”, “expect”, “could”, “should”, “intend”, “estimate”, “anticipate”, “believe”, “remain”, “on track”, “design”, “target”, “objective”, “goal”, “forecast”, “projection”, “outlook”, “prospects”, “plan”, or similar terms. Forward-looking statements are not guarantees of future performance. Rather, they are based on Stellantis’ current state of knowledge, future expectations and projections about future events and are by their nature, subject to inherent risks and uncertainties. They relate to events and depend on circumstances that may or may not occur or exist in the future and, as such, undue reliance should not be placed on them.

Actual results may differ materially from those expressed in forward-looking statements as a result of a variety of factors, including: the ability of Stellantis to launch new products successfully and to maintain vehicle shipment volumes; changes in the global financial markets, general economic environment and changes in demand for automotive products, which is subject to cyclicality; Stellantis’ ability to successfully manage the industry-wide transition from internal combustion engines to full electrification; Stellantis’ ability to offer innovative, attractive products and to develop, manufacture and sell vehicles with advanced features including enhanced electrification, connectivity and autonomous-driving characteristics; Stellantis’ ability to produce or procure electric batteries with competitive performance, cost and at required volumes; Stellantis’ ability to successfully launch new businesses and integrate acquisitions; a significant malfunction, disruption or security breach compromising information technology systems or the electronic control systems contained in Stellantis’ vehicles; exchange rate fluctuations, interest rate changes, credit risk and other market risks; increases in costs, disruptions of supply or shortages of raw materials, parts, components and systems used in Stellantis’ vehicles; changes in local economic and political conditions; changes in trade policy, the imposition of global and regional tariffs or tariffs targeted to the automotive industry, the enactment of tax reforms or other changes in tax laws and regulations; the level of governmental economic incentives available to support the adoption of battery electric vehicles; the impact of increasingly stringent regulations regarding fuel efficiency requirements and reduced greenhouse gas and tailpipe emissions; various types of claims, lawsuits, governmental investigations and other contingencies, including product liability and warranty claims and environmental claims, investigations and lawsuits; material operating expenditures in relation to compliance with environmental, health and safety regulations; the level of competition in the automotive industry, which may increase due to consolidation and new entrants; Stellantis’ ability to attract and retain experienced management and employees; exposure to shortfalls in the funding of Stellantis’ defined benefit pension plans; Stellantis’ ability to provide or arrange for access to adequate financing for dealers and retail customers and associated risks related to the operations of financial services companies; Stellantis’ ability to access funding to execute its business plan; Stellantis’ ability to realize anticipated benefits from joint venture arrangements; disruptions arising from political, social and economic instability; risks associated with Stellantis’ relationships with employees, dealers and suppliers; Stellantis’ ability to maintain effective internal controls over financial reporting; developments in labor and industrial relations and developments in applicable labor laws; earthquakes or other disasters; risks and other items described in Stellantis’ Annual Report on Form 20-F for the year ended December 31, 2023 and Current Reports on Form 6-K and amendments thereto filed with the SEC; and other risks and uncertainties.

Any forward-looking statements contained in this communication speak only as of the date of this document and Stellantis disclaims any obligation to update or revise publicly forward-looking statements. Further information concerning Stellantis and its businesses, including factors that could materially affect Stellantis’ financial results, is included in Stellantis’ reports and filings with the U.S. Securities and Exchange Commission and AFM.

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fosun Pharma Hits the Buyback Button: What's Next?

Updated Category News Views 0

Fosun Pharma's Bold Move Well, if this isn't Fosun Pharma making some noise! Announcing an H-share repurchase plan worth up to HK$1 billion is like setting off fireworks amidst any investor's evening. They're hollering to the market, 'We see value, and we're doubling down on it.' Crunching the Numbers In the first half of 2026, Fosun Pharma's numbers weren't just a flash...

Continue Reading
Harbour BioMed Joins Stock Connect, Boosts Investor Access

Updated Category News Views 1

The Big Leap: Harbour BioMed Joins Stock Connect Well, if this ain't something to get excited about—Harbour BioMed just snagged a spot on the Stock Connect roster. This step isn't just ceremonial. We're talking about real access for mainland Chinese investors to dive directly into the shares of Harbour BioMed (HKEX: 02142.HK) through the Shanghai-Hong Kong and...

Continue Reading
Bad Bunny Super Bowl Halftime Show Sweeps 7 Emmy Wins

Updated Category News Views 3

An Unprecedented Performance: A Halftime Show for the Ages Hold onto your hats, folks—Bad Bunny and his Super Bowl LX Halftime Show have taken home a jaw-dropping seven Emmys at the 78th Emmy Awards. This is uncharted territory for any Super Bowl Halftime Show. Never before has a halftime spectacle swept the Emmys like this. We’re talking about categories such as...

Continue Reading
Asia-Pacific Media Forum Eyes Future Growth Strategies

Updated Category News Views 2

Media Heavyweights Converge in Shenzhen Picture this: Over 400 media moguls from the Asia-Pacific region, huddled together in Shenzhen under that blazing September sun. What for? They're on a mission, inspecting China's shifting landscape, hunting down fresh growth avenues in the Guangdong-Hong Kong-Macao Greater Bay Area. It kicks off within the walls of the Asia-Pacific...

Continue Reading
Aroa Biosurgery Reports Low Infection Rates: A Milestone

Updated Category News Views 1

Peer-Reviewed Study: Aroa's Myriad Shows Low Infection Rates Seems like the folks at Aroa Biosurgery have got something solid to brag about in the world of complex soft tissue reconstruction. The company just released interim results from their massive MASTRR Registry study, and the numbers are looking pretty darn promising. We're talking about a 411-patient analysis...

Continue Reading
EyePoint Stumbles: Legal Eagles Circle Post-Trial Flop

Updated Category News Views 2

EyePoint Slips on Clinical Banana Peel Well, if EyePoint was aiming for a splash, they sure got it—just not the kind they were hoping for. News dropped like a lead balloon when EyePoint announced their Phase 3 DURAVYU trial results for wet age-related macular degeneration, revealing they missed their primary endpoint. And what did that mean for their stock? A death...

Continue Reading
Mermaid Folklore Meets Revolution in New Short Film

Updated Category News Views 2

A Sea Haunting Like No Other Ever feel like history's forgotten tales deserve a fresh spin? Well, this one's shaking it up! Hoyt Dwyer, an Atlanta filmmaker, flips the script on a lesser-known bit from the American Revolution. Yeah, we're talking about Hessian soldiers and sirens here. Just hang on to your hats because this ain't your typical historical retelling. A...

Continue Reading
Creality Rolls Out K3, SPARKX i8 at IFA 2026

Updated Category News Views 12

Creality Struts Its Stuff at IFA 2026 You wouldn't guess 3D printing had anything left to dazzle us with, but Creality has sure put those notions to rest at the IFA 2026 in Berlin. They're rolling out the big guns with fresh tech that pushes both efficiency and sustainability—two big buzzwords these days—and ties a neat little bow on their innovative streak....

Continue Reading
Ice-Rock Avalanches: Future Risks and Urgent Lessons

Updated Category News Views 1

Mounting Threats in Mountain Chains That nightmare on August 26 at Mount Langtang Lirung in Nepal—where an ice-rock avalanche triggered a catastrophic mudslide—brought a harsh reminder that these mountains are cracking wide open. With 31 dead and over 500 souls still unaccounted for, it's a chilling warning about how vulnerable high-altitude regions have become. A...

Continue Reading

Top 5 Most Recently Viewed Articles

Aterian Prepares for Upcoming Earnings Call This Quarter

Updated Category News Views 99

Aterian's Upcoming Financial Results Announcement Aterian, Inc. (Nasdaq: ATER), a prominent player in the consumer products sector, is gearing up to reveal its financial performance for the second quarter. Scheduled for Wednesday in the coming week, this announcement will take place after market closure, providing investors with valuable insights into the company’s...

Continue Reading
Analyzing RTX: Trends in Short Interest and Market Sentiment

Updated Category News Views 176

Understanding RTX's Recent Market Movements RTX Corp has seen a notable shift in its market dynamics recently. The company's short interest, defined as the number of shares sold short but not yet covered, has decreased by 7.63% since the last reporting period. Currently, there are approximately 16.18 million shares sold short, equating to 1.21% of all shares available for...

Continue Reading
Celebrate Christmas Spirit with Personalized PrayerSongs

Updated Category News Views 156

Celebrate the Joy of Christmas with PrayerSong Bring Love Into Your Home with a PrayerSong for Your Family and Friends When the holiday season arrives, the focus shifts beyond material gifts. Instead, it’s about nurturing connections filled with love, faith, and meaningful moments. This Christmas, PrayerSong provides families with a unique opportunity to honor loved...

Continue Reading
Understanding the Short Selling Landscape of Analog Devices

Updated Category News Views 153

Analyzing Short Interest for Analog Devices As investors navigate the ever-changing stock market, understanding short interest can provide valuable insights into market sentiment regarding Analog Devices (NYSE: ADI). Recently, it was reported that Analog Devices has seen a notable increase of 4.11% in its short percent of float. Currently, there are approximately 7.52...

Continue Reading
Future of Clinical Trials: Exploring Market Growth to USD 85.37 Billion

Updated Category News Views 71

Understanding Clinical Trials and Their Importance Clinical trials serve as a fundamental pillar in advancing medical knowledge and enhancing patient care. These trials encompass a detailed and thorough process involving participant recruitment, intervention administration, data collection, and result analysis. The outcomes produced from clinical trials play a crucial...

Continue Reading